Omega-3 fatty acids as adjunctive of antidepressant therapy and its effects on brain-derived neurotrophic factor in serum, monocytes and lymphocytes;Ácidos grasos omega-3 como coadyuvantes del tratamiento antidepresivo y sus efectos sobre el factor neurotrófico derivado del cerebro en suero y en células mononucleares

Archivos Venezolanos de Farmacologia y Terapeutica

Volumn 30, Issue 4, 2011, Pages 72-78

  González, Alfonso ^a,b   Mata, Salvador ^a,b   Sánchez, Paul ^b   González, Dacia ^b   Urbina, Mary ^c   Fazzino, Fili ^c   Lima, Lucimey ^b,c  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b Hospital Vargas de Caracas   (Venezuela)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Brain derived neurotrophic factor; Major depression; Mononuclear cells; Omega 3 fatty acids

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO;

ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; LYMPHOCYTE; MAJOR DEPRESSION; MONOCYTE; MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 80555145946     PISSN: 07980264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry 1985; 142:1017-1031
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. J Neuropsychiatry Clin Neurosci. 1995;7:524-3
3. Heninger GR, Delgado PL, Chamey DS. The revised monoamine theory of depression: a modulatory role for monoamines based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996; 29: 2-11
4. Delgado Pl, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000; 61 Suppl 1: 5-12
5. Tanis KQ, Newton SS, Duman RS. Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development. CNS Neurol Disord Drug Targets 2007; 6:151-160.
6. Smith MA, Makino S, Kvetnansky R, Post RM. Stress alters the express of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15:1768-1777
7. Rasmussen A, Shi L, Duman RS. Down-regulation of BDNF mRNA in the hippocampal dentate gyrus after re-axposure to cues previously associated with footshock. Neuropsychopharmacology 2002; 27:133-142.
8. Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA: Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry 2004; 55:708-714
9. Duman RS. Depression: A case of neuronal life and death? Biol Psychiatry 2004; 56:140-145.
10. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59:1116-1127
11. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antide pressant drug treatments. J Neurosci 1995;15:7539-7547
12. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMPresponse element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16:2365-2372
13. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20:9104-9110
14. Coppell A, Pei Q, Zetterstron TSC. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44:903-910
15. Lauterborn J, Truong GS, Baudry M, Bi X, Lynch G, Gall CM. Chronic elevation of brain derived neurotrophic factor by ampakines. J Pharmacol Exp Ther 2003; 307:297-305
16. Marvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001;18:247-258
17. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev 2003; 8: 410-425
18. Logan AC. Omega-3 fatty acids and major depression: a primer for the mental health professional. Lip Health Dis 2004; 3:1-8
19. Bourre JM, Dumont O, Piciotti M, Clement M, Chaudiere J, Bonneil M, Nalbone G, Lafont H, Pascal G, Durand G. Essentiality of omega 3 fatty acids for brain structure and function. World Rev Nutr Diet 1991; 66:103-117
20. Maes M, Smith RS: Fatty acids, cytokines, and major depression. Biol Psychiatry 1998; 43:313-314
21. Suarez EC, Krishnan RR, Lewis JG. The relation of severity of de pressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 2003; 65:362-368
22. Barouch, R. Differential of neurotrophin expression by mitogens and neurotransmitters in mouse lymphocytes. J. Neuroimmunol 2000; 103: 112-121
23. Moalen G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, Schwartz M. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J. Autoimmun 2000; 15: 331-345
24. Bayas, A. Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells. Neurosci Lett 2003; 3335: 155-158
25. Ziemssen T, Kûmpfelt T, Schneider H, Klinkert WE, Neuhaus O, Hohfeld R. Secretion of brain-derived neurotrophic factor by glatimer acetate-reactive T-helper cell lines: implications for multiple sclerosis therapy. J Neurol Sci 2005; 233: 109-112
26. Schulte-Herbrûggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 2005; 160: 204-209.
27. Môssner R, Daniel S, Albert D, Heils A, Okladnova O, Schmitt A, Lesch KP. Serotonin transporter function is modulated by brainderived neurotrophic factor (BDNF) but not by nerve growth factor (NGF). Neurochem Int 2000; 36: 197-202
28. Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD.Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 171-176
29. Horrobin DF. A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E). Prog Drug Res 2002; 59:171-199
30. Boure JM. Omega-3 fatty acids in psychiatry. Med Sci (Paris) 2005; 21: 216-221
31. Nemets B, Stahl Z, Belmaker RH. Addiction of omega-3 fatty acids to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-479
32. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-919
33. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. Br J Psychiatry 2006;188:46-50
34. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407-12
35. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13:267-271
36. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Publishing; 2000
37. First MB, Spitzer RL, Gibbon M, Williams JBW. Entrevista Clínica Estructurada para los trastornos del eje I del DSM-IV, Versión Clínica. Barcelona: Masson; 1999
38. Hamilton MA. A rating scale of depression. J. Neurol Neurosurg Psychiatry 1960; 23:56-62
39. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN. Brain-derived neurotrophic factor gene and protein expresión in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 2010; 30:645-651
40. Aznar S, Klein AB, Santini MA, Knudsen GM, Henn F, Gass P, Vollmayr B. Aging and depression vulnerability interaction results in decreased serotonin innervation associated with reduced BDNF levels in hippocampus of rats bred for learned helplessness. Synapse 2010; 64:561-565
41. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57:1068-1072
42. Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF level in depressive patients. J Affect Disord 2007; 101:239-244
43. Lee BH, Kim YK. Reduced platelet BDNF level in patients with major depression. Prog Neuropharmacol Biol Psychiatry. 2009; 33:849-853
44. Barbosa IG, Huguet RB, Mendoca VA, Neves FS, Reis HJ, Bauer ME, Janka Z, Palotás A, Teixeira AL. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett 2010; 475:95-98
45. Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, Soekadar S, Demosthenous M, Regenold WT. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 2007; 68:512-517
46. Caruncho HJ, Rivera-Baltanás. Biomarkers of depression. Rev Neurol 2010; 50:470-476
47. Biocchio-Chiavetto L, Bagnardi V, Zanardi R, Molteni R, Gabriela Nielsen M, Placentino A, Giovanni C, Rillosi L, Ventriglia M, Riva MA, Gennarelli M. Serum and plasma BDNF levels in major depression. A replication study and meta-analyses. World J Biol Psychiatry 2010; (in press)
48. Lee BH, Kim YK. BDNF mRNA expression in peripheral blood mononuclear cells was decreased in depressive patients who had or had not recently attempted suicide. J Affect Disord 2010; (in press)
49. Brunoni AR, Cysneiros RM. Lower mRNA BDNF expression in lymphocytes endophenotype or epiphenomenon for major depression? Prog Neuropharmacol Biol Psychiatry 2010; (in press)
50. Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 2008; 195:186-193.
51. Fauchais AL, Lalloué F, Lise MC, Boumediene A, Preud́homme JL, Vidal E, Jauberteau MO. Role of endogenous brain-derived neurotrophic factor and sortilin in B cell survival. J Immunol 2008; 181:3027-3038
52. Linker R, Gold R, Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination.Crit Rev Immunol 2009; 29:43-68
53. Koch JM, Hinze-Selch D, Stingele K, Huchzermeier C, Goder R, Seeck-Hirschner M, Aldenhoff JB. Changes in CREB phosphorylation and BDNF plasma levels during psychoterapy of depression. Psychother Psychosom 2009; 78:187-192
54. Blondeau N, Nguemeni C, Debruyne DN, Piens M, Wu X, Pan H, Hu X, Gandin C, Lipsky RH, Plumier JC, Marini AM, Heurteaux C. Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuropsychopharmacology 2009; 34:2548-2559
55. Stahl LA, Begg DP, Weisinger RS, Sinclair AJ. The role of omega-3 fatty acids in mood disorders. Curr Opin Invest Drugs 2008; 9: 57-64
56. Rao JS, Ertley RN, Lee HJ, DeMar JC Jr, Arnold JT, Rapoport SI, Bazinet RP. N-3 Polyunsaturated fatty acids deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 2007; 12:36-46
57. Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypothesis 2005; 64:533-538
58. Motulsky H. Intuitive Biostatistics. Oxford University Press, New York, 1995
59. Wells TT, Beevers CG, McGeary JE. Serotonin transporter and BDNF genetic variants interact to predict cognitive reactivity in healthy adults. J Affect Disord 2010; 126: 223-229